Website Link:
Contact us:
Phone:
Year of Foundation:
Adjuvant is a new type of venture capital firm. Our mission is simple: use venture capital strategies to deploy capital in the most promising public health technologies and ensure they are made accessible to those who need them most. We are backed by a number of prominent foundations and international development organizations seeking to improve public health globally, with a particular emphasis on low- and middle-income countries. We see enormous opportunity in historically overlooked market segments, and we leverage our unique expertise to translate these opportunities into social and financial returns. Our investment strategy is biased toward affordable new or improved vaccine technologies, but we actively invest in therapeutics, diagnostics, and devices as well.
We invest and partner with companies developing innovative technologies addressing high-burden and neglected infectious diseases, maternal and child health, nutrition, and reproductive and sexual health. Our team has supported numerous important vaccine programs in development – including those for Group B Strep, shigella, chikungunya, and VZV, among others – and we continue to look for developing country vaccine manufacturers to partner with and invest in to help increase access to medicines across the globe.